Recent News for JAGX - Jaguar Animal Health, Inc.

Date Title
Mar 27 Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Mar 20 GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Feb 23 Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Feb 15 Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Feb 14 Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
Feb 12 Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Jan 30 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Jan 29 Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
Jan 25 Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
Jan 4 Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Back to the Main JAGX Page...